Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Hears Echo Of Managed Care In Medicare: “Minor Negative” At First

Executive Summary

Wyeth believes the implementation of the Medicare prescription drug benefit is likely to parallel the impact of the emergence of managed care on the pharmaceutical industry

You may also be interested in...



Lilly Sees Benefit From Medicare Rx In Short Term, But Risk For Zyprexa

Lilly expects a "modest benefit" from implementation of Medicare Part D that could later be offset by increased pricing pressures

Lilly Sees Benefit From Medicare Rx In Short Term, But Risk For Zyprexa

Lilly expects a "modest benefit" from implementation of Medicare Part D that could later be offset by increased pricing pressures

Wyeth More Optimistic About Medicare Rx; Protonix May Benefit

Wyeth is becoming more optimistic about the potential upside of the Medicare prescription drug benefit, Wyeth North America President Joseph Mahady said during the Smith Barney Citigroup Healthcare Conference in Washington, D.C. March 30

Topics

UsernamePublicRestriction

Register

PS045263

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel